Evidence Level:Sensitive: C3 – Early Trials
Title:
Efficacy and mechanism of action of NKTR-255, a polymer-conjugated IL-15 receptor agonist in hematological tumors.
Excerpt:NKTR-255 demonstrated synergistic activity and provided a long-term survival benefit when combined with daratumumab or rituximab in the CD38 and CD20-expressing lymphoma mouse models...
DOI:10.1200/JCO.2019.37.15_suppl.e19512